Navigation Links
Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
Date:10/1/2013

ral commonly used medications. Also, they offer insight into the clinical profile of the compounds for researchers and healthcare professionals looking for potential new treatment options for patients with HCV.

"We are pleased to see the presentation of the final results from STARTVerso1, 2 and 3, Boehringer Ingelheim's pivotal Phase 3 program in our hepatitis C portfolio, as well as other important analyses evaluating various patient subgroups at this year's AASLD meeting," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "These data, combined with that of our interferon-free trial, SOUND-C3, are evidence of our commitment to researching new therapeutic options for patients infected with HCV."

Faldaprevir and deleobuvir are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Boehringer Ingelheim's abstracts can be accessed on the AASLD website today at www.aasld.org.

Poster PresentationsTitleLead Author Presentation Details Effect of multiple oral doses of

faldaprevir on the multiple dose

pharmacokinetics of a combination

oral tablet of ethinylestradiol and

levonorgestrel in healthy

premenopausal female volunteers

J. Sabo

ID# 482
Session: HCV Therapy: The
Developmental Pipeline
Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall Mass balance, metabolic profile

and the role of hepatic and

bacterial enzymes in the

metabolism of the HCV

polymerase inhibitor, deleobuvir

(BI 207127)

R. Sane

ID# 491
Session: HCV Therapy: The
Developmental Pipeline
Date: Sat, Nov. 2
Time: 2:00 PM – 7:30 PM ET
Location: Poster Hall Pharmacokinetics, safety, and
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
2. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
3. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
4. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
5. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
6. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
9. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
10. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
11. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... 22, 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... Day and Panera (Nasdaq: PNRA - Free Report ) as ... analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), ... SHPG - Free Report ). Here is a ... the Day : The biotech bull market is ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... of Hospital TVs Today Lincor announced general ... Patient Engagement solution that delivers a range of education, ... sets.      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... in defining point of care patient engagement to bedside ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... Medical Imaging (RMI) in Flint announced today that it is ... Breast Magnetic Resonance Imaging (MRI) by the American College of ... the Breast MRI Accreditation Program to recognize imaging ... for Breast MRI. RMI received this new distinction after a ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... trial program for APD597 (JNJ-38431055) under its collaboration with ... APD597 and has notified Arena that it is terminating ... GPR119 agonist intended for the treatment of type 2 ...
Cached Medicine Technology:Exciting Healthcare News for Women of Mid Michigan 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 3Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 4Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 5
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Mi40x , the latest guide from ... people how they can use a simple 4-minute trick to ... of weeks has caught the attention of Shane Michaels, prompting ... the most well-known bodybuilders in the industry, and if he ... that in itself is a testament to how effective this ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Mueller Sports ... Plantar Fasciitis, an exciting new product that provides non-drug ... to stay active while you heal. The package includes ... truly a new technology – it is not kinesiology ... FasciaDerm® PFTape™ System for Plantar Fasciitis is ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... leading cause of infections in hospitals can be dramatically reduced, ... The program, cheap and easy to implement, is sparking intrigue ... , HPMC is the first acute care facility to successfully ... urine, currently under increased scrutiny for causing deadly infections in ...
... ,missiles, to hurl at visitors for his own amusement, report ... Santino, a male chimp at the Furuvik Zoo in Lund, ... the zoo opened collecting rocks and other "ammunition" to hurl ... around mid-morning. , He stored the items at various sites ...
... to Provide Information on Medicare Advantage Special Needs ... ROCK, Ark., March 9 A series of ... with chronic illness maintain a healthy lifestyle and ... for their unique needs will be offered during ...
... National Commander of the Disabled American Veterans begins a ... for budget reform legislation to ensure sufficient, timely and ... urging them to reject a contentious proposal that would ... from the government,s side of the ledger to insurance ...
... in the international journal Chest , by Neil ... disease (COPD) who breathed a mix of 60% helium ... to exercise longer and harder than those who breathed ... significant because research has shown that patients who perform ...
... announced in 2004 an initiative to have the health records of all ... this daunting task. However, unfortunately, unsatisfactory progress has been made to ... goal will likely be met by the 2014 deadline previously announced. ... ...
Cached Medicine News:Health News:Hollywood Hospital's Trend-Setting Program to Drastically Cut Infections 2Health News:Thinking Man's Chimp Shows 1st Animal 'Planning' 2Health News:Thinking Man's Chimp Shows 1st Animal 'Planning' 3Health News:Free Seminars Offered to Arkansas Seniors with Diabetes and Other Chronic Illnesses 2Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:Helium helps lung patients breathe easier 2Health News:EMRConsultant.com Supports the American Recovery and Reinvestment Act of 2009 2
Reusable shielded cable...
... The STREP A OIA MAX test ... of Group A Strep with a simple, ... minutes. This combination of performance, speed, and ... care while reducing overall costs for diagnosing ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... a high performance assay for the undifferentiated ... with a simple, easy-to-use test that provides ... Assay advantages include superior performance with mucoid ... 14-day viral culture enables you to decrease ...
Medicine Products: